Company news
Cynata Therapeutics Limited (ASX:CYP) news
Cynata Therapeutics Limited news releases on 6ix. Latest, Jul 2, 2018: Cynata Enters Development Partnership with RCSI
Press releases — page 4
Cynata Enters Development Partnership with RCSI
July 1, 2018
Product Development Program Update & Investor Presentation
June 25, 2018
Positive 28-day Clinical Trial Data in Cohort B
June 20, 2018
Research Collaboration with UNSW for Coronary Artery Disease
June 18, 2018
Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
June 11, 2018
Cynatas MSCs Effective in Model of Diabetic Wounds
May 30, 2018
$5.2m placement of shares to Fidelity International
May 29, 2018
Enrolment Completed in Cynatas Phase 1 Clinical Trial
May 23, 2018
Notice of Allowance from EPO for Patent Application
May 7, 2018
March 2018 Quarterly Report
April 27, 2018
CYP Completes Patent Application related to CAR-T Therapy
April 19, 2018
Further US Patent Granted for Cynata Cymerus Technology
April 10, 2018
FDA Grants Orphan Drug Designation to Cyanta for CYP-001
March 27, 2018
Excellent Data from Final Preliminary Evaluation Period
February 26, 2018
Cynata Engineered MSC Study Review Reveals Promising Results
February 4, 2018
December 2017 Quarterly Report
January 30, 2018
Cynata Treats First Patient in Cohort B
January 23, 2018
Cyanta & Celularity Inc Execute MOU
January 22, 2018
Encouraging Early Data-Cynata Clinical Trial Proceeds
January 21, 2018
Final Preclinical Asthma Study Confirms Efficacy
December 11, 2017
United States Patent Allowance for Core Cynata Technology
December 7, 2017
Enrolment Completed in 1st Cohort of Cynata Clinical Trial
November 14, 2017
September 2017 Quarterly Report
October 27, 2017
Notice of Annual General Meeting/Proxy Form
October 9, 2017
Cynata to Increase Exposure in Japan
October 8, 2017
US Patent Granted for Cynata Cymerus Technology
September 27, 2017
Health Canada Meeting Advances CYP Global Development Plans
August 31, 2017
Positive Data from CYP MSCs in 2nd Preclinical Asthma Study
August 23, 2017
June 2017 Quarterly Report
July 28, 2017
FDA Meeting Provides Clear Path for US Development Plans
July 4, 2017
Cynata Therapeutics GvHD Clinical Trial & Corporate Progress
June 27, 2017
CYP MSC Data in Asthma Model Published in Sceintific Journal
June 22, 2017
Cynata Files New Patent Application for Cymerus in Oncology
June 20, 2017
United States Patent for Core Cynata Technology
June 19, 2017
Treatment Commences in Cynatas World First Clinical Trial
May 16, 2017
March 2017 Quarterly Report
April 26, 2017
Cynata Advances to Pre-IND Meeting with US FDA
April 18, 2017
CYP Files for New Patent for Oncology Applications
April 12, 2017
CYP in Collaboration on Acute Respiratory Distress Syndrome
April 10, 2017
Cynata Partner apceth GmbH & Co Completes Cymerus Evaluation
March 30, 2017
CYP Advances Development of Cymerus for Treatment of Asthma
March 1, 2017
Final GvHD Preclinical Report Confirms Treatment Benefit
February 5, 2017
Positive Preliminary Data from Preclinical HeartAttack Study
February 1, 2017
Appendix 4C - quarterly
January 25, 2017
Cynata Successfully Completes Capital Raising
January 22, 2017
Cynata & FUJIFILM Sign Strategic Partnership Agreement
January 18, 2017
Cynatas Clinical Study Approved in Austrralia
December 15, 2016
Cynata Receives NHS HRA Approval for Clinical Study
December 12, 2016
Cynata Files Further Patent Application
November 28, 2016
Cynata Receives $1.749m R&D Tax Incentive Refund
November 15, 2016